Rahul D. Ballal Net Worth

The estimated Net Worth of Rahul D. Ballal is at least $248 Tausend dollars as of 11 August 2024. Rahul Ballal owns over 2,302 units of Imara Inc stock worth over $50,509 and over the last 4 years Rahul sold IMRA stock worth over $197,366.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rahul Ballal IMRA stock SEC Form 4 insiders trading

Rahul has made over 7 trades of the Imara Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Rahul exercised 2,302 units of IMRA stock worth $14,549 on 11 August 2024.

The largest trade Rahul's ever made was selling 32,861 units of Imara Inc stock on 22 February 2023 worth over $153,132. On average, Rahul trades about 4,764 units every 111 days since 2020. As of 11 August 2024 Rahul still owns at least 7,992 units of Imara Inc stock.

You can see the complete history of Rahul Ballal stock trades at the bottom of the page.

What's Rahul Ballal's mailing address?

Rahul's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Imara Inc

Over the last 5 years, insiders at Imara Inc have traded over $7,889,059 worth of Imara Inc stock and bought 11,496,717 units worth $107,874,489 . The most active insiders traders include David M Mott, Lundbeck A S H und Capital Management, L.P.Ra .... On average, Imara Inc executives and independent directors trade stock every 23 days with the average trade being worth of $1,965,179. The most recent stock trade was executed by Michael Gray on 22 February 2023, trading 9,856 units of IMRA stock currently worth $46,028.

What does Imara Inc do?

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.

Complete history of Rahul Ballal stock trades at Agios Pharmaceuticals Inc und Imara Inc

Imara Inc executives and stock owners

Imara Inc executives and other stock owners filed with the SEC include:

• Rahul D. Ballal,
  Chief Executive Officer
• Edward R. Conner,
  Director
• Enterprise Associates 14, L...,
  
• Springs Capital Management ...,
  
• Lundbeck A S H,
  10% owner
• City Capital Llc Bay City C...,
  
• Venture Investments, Llc Al...,
  10% owner
• Invest A/S Lundbeckfond,
  10% owner
• Bioscience Plc Arix Bioscie...,
  
• Capital Management, L.P.Ra ...,
  
• Advisors Llc Orbi Med Capit...,
  
• James G Mc Arthur,
  Director
• Carlbay City Capital Llc Ba...,
  
• Mette Kirstine Agger,
  Director
• David P Bonita,
  Director
• Barbara Dalton,
  Director
• Sara M. Nayeem,
  Director
• David M Mott,
  Director
• Inc Pfizer Ventures (Us) Ll...,
  
• Enterprise Associates 14, L...,
  
• Michael Gray,
  CFO & COO
• Kenneth Attie,
  SVP, CMO
• Laura A Williams,
  Director
• Carl Goldfischer,
  Director
• Mark Chin,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Braden Michael Leonard,
  10% owner
• Enterprise Associates 14, L...,
  
• Enterprise Associates 14, L...,
  
• Enterprise Associates 14, L...,
  
• Capital Lp Commodore,
  10% owner